Hologic, Inc. (NASDAQ:HOLX) Stake Boosted by National Bank of Canada FI

National Bank of Canada FI raised its holdings in shares of Hologic, Inc. (NASDAQ:HOLX) by 36.2% in the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 260,002 shares of the medical equipment provider’s stock after purchasing an additional 69,090 shares during the period. National Bank of Canada FI owned about 0.12% of Hologic worth $18,749,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds also recently modified their holdings of the business. Public Sector Pension Investment Board raised its stake in Hologic by 13.7% during the third quarter. Public Sector Pension Investment Board now owns 9,959 shares of the medical equipment provider’s stock worth $811,000 after acquiring an additional 1,200 shares during the period. Chevy Chase Trust Holdings LLC raised its position in shares of Hologic by 13.9% during the 3rd quarter. Chevy Chase Trust Holdings LLC now owns 186,891 shares of the medical equipment provider’s stock worth $15,224,000 after purchasing an additional 22,821 shares during the period. HighTower Advisors LLC raised its position in shares of Hologic by 9.8% during the 3rd quarter. HighTower Advisors LLC now owns 22,603 shares of the medical equipment provider’s stock worth $1,832,000 after purchasing an additional 2,012 shares during the period. Janus Henderson Group PLC lifted its holdings in shares of Hologic by 2.9% in the 3rd quarter. Janus Henderson Group PLC now owns 28,776 shares of the medical equipment provider’s stock worth $2,344,000 after purchasing an additional 800 shares during the last quarter. Finally, Royal London Asset Management Ltd. grew its stake in Hologic by 6.0% during the 3rd quarter. Royal London Asset Management Ltd. now owns 335,011 shares of the medical equipment provider’s stock worth $27,290,000 after buying an additional 19,095 shares during the last quarter. 94.73% of the stock is owned by institutional investors and hedge funds.

Hologic Price Performance

NASDAQ HOLX opened at $61.69 on Friday. Hologic, Inc. has a 1 year low of $59.06 and a 1 year high of $84.67. The stock’s 50-day moving average price is $64.51 and its two-hundred day moving average price is $72.80. The company has a market cap of $13.84 billion, a PE ratio of 19.46, a PEG ratio of 2.14 and a beta of 0.97. The company has a current ratio of 3.49, a quick ratio of 2.78 and a debt-to-equity ratio of 0.52.

Hologic (NASDAQ:HOLX) last issued its quarterly earnings results on Wednesday, February 5th. The medical equipment provider reported $1.03 EPS for the quarter, beating the consensus estimate of $1.02 by $0.01. Hologic had a net margin of 18.42% and a return on equity of 19.72%. On average, analysts predict that Hologic, Inc. will post 4.28 EPS for the current year.

Analysts Set New Price Targets

HOLX has been the subject of several analyst reports. Leerink Partnrs downgraded shares of Hologic from a “strong-buy” rating to a “hold” rating in a report on Thursday, February 6th. William Blair restated an “outperform” rating on shares of Hologic in a research report on Thursday, February 6th. Royal Bank of Canada dropped their price target on shares of Hologic from $88.00 to $85.00 and set a “sector perform” rating on the stock in a research note on Thursday, February 6th. Needham & Company LLC downgraded Hologic from a “buy” rating to a “hold” rating and set a $90.00 price objective for the company. in a research report on Monday, February 3rd. Finally, Jefferies Financial Group started coverage on Hologic in a research report on Tuesday, December 10th. They issued a “hold” rating and a $85.00 target price on the stock. Eleven equities research analysts have rated the stock with a hold rating, six have assigned a buy rating and one has issued a strong buy rating to the company. According to MarketBeat.com, the company presently has an average rating of “Hold” and a consensus target price of $84.62.

Hologic Profile

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.